Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.

Ami V. Desai,Giles W. Robinson,Ellen M. Basu,Jennifer Foster,Karen Gauvain,Amit J. Sabnis,Suzanne Shusterman,Margaret E. Macy,Luke Maese,Janet M. Yoon,Thomas Cash,Mohamed S. AbdelBaki,Kellie Nazemi,Brian Weiss,Saibah Chohan,Alison Cardenas,Katherine E. Hutchinson,Guillaume Bergthold,Amar J. Gajjar,Elizabeth Fox

Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.

2020

107Background: The phase 1/2 STARTRK-NG trial (NCT02650401) is evaluating entrectinib, a CNS-penetrant oral inhibitor of TRK, ROS1 and ALK tyrosine kinases, in children and adolescents < 21 years o...

Keywords:

Oncology
Tyrosine kinase
Trk receptor
Pathology
Internal medicine
ROS1
Refractory
CNS TUMORS
Entrectinib
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations